# Inferential challenges for machine learning applications in precision medicine and data-driven decision science

Michael R. Kosorok

Department of Biostatistics Department of Statistics and Operations Research University of North Carolina at Chapel Hill

January 16, 2018

### Acknowledgments

- Many co-authors helped:
  - Current and former students: Emily Butler, Guanhua Chen, Jingxiang Chen, Yifan Cui, Anna Kahkoska, Daniel Luckett, Yingqi Zhao, Xin Zhou, and Ruoqing Zhu
  - Other colleagues: SM Davis, H Fu, X He, U Khan, EB Laber, Y Liu, DM Maahs, E Mayer-Davis, N Mayer-Hamblett, and D Zeng
- This project was funded in part by US NIH grants P01 CA142538 and UL1 TR001111, and US NSF grant DMS-1407732, among others.

### Outline

### Introduction

Outcome weighted learning

Precision medicine in mHealth

Estimation and Optimization of Composite Outcomes

Overall conclusions and future work

### **Precision Medicine**

### Precision medicine

- Developing targeted treatments which leverage patient heterogeneity
- Empirically based, scientifically rigorous, reproducible, and generalizable (i.e., will work with future patients)
- Philosophically similar to traditional personalized medicine but with greater empirical rigor
- Scientific tools:
  - Biomedical knowledge based on current state of science
  - Data (potentially integrated across many platforms)
  - Knowledge driven vs. data driven approaches
  - Computational, mathematical and statistical tools

# **Clinical focus**

We want to make the best treatment decisions based on data:

- The single-decision setting:
  - A patient presents with a disease and we need to decide what treatment (or dose) to give from a list of choices
  - We want to make the best decision based on available baseline patient-level feature data (dynamic treatment regime)
- The multi-decision setting:
  - Treat patients for diseases with multiple treatment decision times based on continually accrued patient-level data
  - The best decisions take into account delayed effects
- ▶ Real time decision making in mHealth:
  - A large number of decisions need to be made in real time
  - Technical and practical challenges for implementing
- Decision making on social networks and other complex environments

### Statistics and machine learning

- What are the data analytic tasks?
  - Estimate dynamic treatment regimes (DTRs) a.k.a. Individualized treatment rules (ITRs)
  - Inference and prediction for DTRs
  - Etiology?
- What role does statistics play?
  - Estimation
  - Inference: consistency, accuracy (error bounds), confidence regions, efficiency, etc.
- How can machine learning help?
  - Provide a rich set of estimation and prediction tools
  - Perform certain data-drive tasks unusual for statistics: policy learning, reinforcement learning, inverse reinforcement learning, etc.

### Outline

### Introduction

### Outcome weighted learning

Precision medicine in mHealth

Estimation and Optimization of Composite Outcomes

Overall conclusions and future work

## Single decision setting

- Let X be the vector of patient tailoring variables, A the choice of treatment given, and R the clinical outcome (with larger being better).
- An obvious approach is to first estimate the Q-function

$$Q(x,a) = E[R|X = x, A = a],$$

through regression of R on (X, A), and invert to obtain

$$\hat{d}(x) = \operatorname*{argmax}_{a} \hat{Q}(x, a).$$

Potential issue: Why estimate all of Q(x, a) when focus is on d(x)?

# Value function and optimal individualized treatment rule

Let P be the distribution of (X, A, R), with treatments randomized via π(A|X), and P<sup>d</sup> the distribution of (X, A, R), with treatments chosen according to d. The value function of d (Qian & Murphy, 2011) is

$$V(d) = E^{d}(R) = \int R dP^{d} = \int R \frac{dP^{d}}{dP} dP = E\left[\frac{I(A=d)}{\pi(A|X)}R\right].$$

Optimal Individualized Treatment Rule:

$$d^* \in \operatorname*{argmax}_{d} V(d).$$

$$E(R|X, A = 1) > E(R|X, A = -1) \Rightarrow d^*(X) = 1$$
$$E(R|X, A = 1) < E(R|X, A = -1) \Rightarrow d^*(X) = -1$$

Outcome weighted learning (OWL or O-learning)

Optimal Individualized Treatment Rule d\*

Maximize the value Minimize the risk

$$E\left[\frac{I(A=d(X))}{\pi(A|X)}R\right] \quad E\left[\frac{I(A\neq d(X))}{\pi(A|X)}R\right]$$

- For any rule d, d(X) = sign(f(X)) for some function f.
- Empirical approximation to the risk function:

$$n^{-1}\sum_{i=1}^n \frac{R_i}{\pi(A_i|X_i)}I(A_i\neq \operatorname{sign}(f(X_i))).$$

 Computational challenges: non-convexity and discontinuity of 0-1 loss.

### Using a support vector machine (SVM) approach

Objective Function: Regularization Framework

$$\min_{f} \left\{ \frac{1}{n} \sum_{i=1}^{n} \frac{R_{i}}{\pi(A_{i}|X_{i})} \phi(A_{i}f(X_{i})) + \lambda_{n} \|f\|^{2} \right\}.$$
(1)

- φ(u) = (1 − u)<sup>+</sup> is the hinge loss surrogate, ||f|| is some norm for f, and λ<sub>n</sub> controls the penalty on f.
- A linear decision rule: f(X) = X<sup>T</sup>β + β₀, with ||f|| as the Euclidean norm of β.
- Estimated individualized treatment rule:

$$\hat{d}_n = \operatorname{sign}(\hat{f}_n(X)),$$

where  $\hat{f}_n$  is the solution to (1).

### **Results for O-Learning**

- Can use kernel trick to extend to nonparametric decision rule (e.g., the Gaussian kernel).
- Fisher consistent, consistent, and model robust.
- Risk bounds and convergence rates similar to those observed in SVM literature (Tsybakov, 2004).
- Excellent simulation results and data analysis of Nefazodone-CBASP clinical trial (Keller et al., 2000).
- ▶ Promising performance overall (Y.Q. Zhao, et al., 2012).
- An example of a policy learning approach (see also B. Zhang, et al., 2012; Athey and Wager, 2017; others).
- Opens door to a unique application of machine learning techniques to personalized medicine.
- Not semiparametric efficient in finite-dimensional setting.

# **O-Learning Extensions**

- Multiple decision times (Zhao et al, 2015, JASA)
- Location invariance for outcome/utility (Zhou et al, 2017, JASA)
- More than two treatment options:
  - Ordinal treatment options (Chen et al, In press, Biometrics)
  - Nonordinal treatments (Rashid et al, submitted)
- Censored data (Zhao et al, 2015, *Biometrika*; Cui et al, 2017, *EJS*)
- For observational data, propensity score estimation is needed

### **O-Learning and Related Extensions**

- Continuous treatment options
  - Chen G, Zeng D, and Kosorok MR (2016). Personalized dose finding using outcome weighted learning (with discussion and rejoinder). JASA 111:1509-1547.
  - Consistency and error bounds are difficult, and inference is unclear
- V-learning for (nearly) continuous time and mHealth (Luckett et al, submitted)
- Multiple competing utilities
  - Incorporating patient preferences (Butler et al, In press, Biometrics)
  - Inverse reinforcement learning to infer composite utility (Luckett et al, submitted)

### Outline

Introduction

Outcome weighted learning

Precision medicine in mHealth

Estimation and Optimization of Composite Outcomes

Overall conclusions and future work

### Precision medicine in mHealth

Overall research goal:

 Develop estimation techniques (using data collected with mobile devices) for dynamic treatment regimes (which can be implemented as personalized mHealth interventions)

Motivating example: type 1 diabetes

- Understand type 1 diabetes (T1D) and how it is managed (minimizing hypo- and hyperglycemia, controling weight)
- Develop tailored mHealth interventions for T1D management

### The glucose-insulin dynamical system

A day in the life of a T1D patient:



Figure 1: Plot of glucose, insulin, physical activity, and food intake.

# Mobile technology in T1D care

Mobile devices can be used to administer treatment and assist with data collection in an outpatient setting, including

- Continuous glucose monitoring
- Accelerometers to track physical activity
- Insulin pumps to administer and log injections automatically

These technologies can be incorporated using mobile phones.

### **Research goals**

Methodological goals:

- Estimate dynamic treatment regimes for use in mobile health
- Infinite time horizon, minimal modeling assumptions
- Observational data with minute-by-minute observations
- Online estimation to facilitate real-time decision making
   Clinical goals:
  - Provide patients information on the best actions to stabilize glucose
  - Recommendations that are dynamic and personalized to the patient

### **Conceptual framework**

- ► We use a Markov decision process (MDP) context
- One potential approach is to use infinite horizon Q-learning (models state-value as a function of action assuming all future actions are optimal):
  - Ertefaie A (2014). Constructing dynamic treatment regimes in infinite-horizon settings. arXiv preprint arXiv:1406.0764.
- We developed V-learning which uses a policy learning approach (models state-value as a function of policy):
  - Luckett DJ, Laber EB, Kahkoska AR, Maahs DM, Mayer-Davis E, Kosorok MR (2016). Estimating dynamic treatment regimes in mobile health using V-learning. arXiv preprint arXiv:1611.03531.

### Markov decision processes (MDP's)

Assume the data consist of *n* i.i.d. trajectories  $(\mathbf{S}^1, A^1, \mathbf{S}^2, \dots, \mathbf{S}^T, A^T, \mathbf{S}^{T+1})$ where  $\mathbf{S}^t \in \mathbb{R}^p$ ,  $A^t \in \mathcal{A}$ , and there exists a known utility function  $U^t = u(\mathbf{S}^{t+1}, A^t, \mathbf{S}^t)$ .



Figure 2: Graphical depiction of a Markov decision process.

Treatment regimes:

- ▶ Let B(A) be the space of distributions on A
- A policy,  $\pi$ , is a function  $\pi : \operatorname{dom} \mathbf{S}^t \to \mathcal{B}(\mathcal{A})$
- π(a<sup>t</sup>; s<sup>t</sup>) gives the probability of selecting a<sup>t</sup> ∈ A when in state S<sup>t</sup> = s<sup>t</sup>

### The state-value function

The state-value function is

$$V(\pi, \mathbf{s}^t) = \mathbb{E}\left\{\sum_{k\geq 0} \gamma^k U^{*(t+k)}(\pi) | \mathbf{S}^t = \mathbf{s}^t
ight\}$$

for a discount factor  $\gamma \in (0, 1)$ 

- ► For a distribution,  $\mathcal{R}$ , define the value of  $\pi$ ,  $V_{\mathcal{R}}(\pi) = \int V(\pi, \mathbf{s}) d\mathcal{R}(\mathbf{s})$
- ► For a class of regimes,  $\Pi$ , the optimal regime,  $\pi_{\mathcal{R}}^{opt} \in \Pi$ , satisfies

$$V_{\mathcal{R}}(\pi^{\mathrm{opt}}_{\mathcal{R}}) \geq V_{\mathcal{R}}(\pi)$$

for all  $\pi \in \Pi$ 

### An estimating equation for $V(\pi, \mathbf{s})$

Let 
$$\mu^t(a^t; \mathbf{s}^t) = \Pr(A^t = a^t | \mathbf{S}^t = \mathbf{s}^t)$$
 for each  $t \ge 1$ .

#### Lemma

Assume strong ignorability, consistency, and positivity. Let  $\pi$  denote an arbitrary regime and  $\gamma \in (0,1)$  a discount factor. Then, provided interchange of the sum and integration is justified, the state-value function of  $\pi$  at  $\mathbf{s}^t$  is

$$V(\pi, \mathbf{s}^{t}) = \sum_{k \ge 0} \mathbb{E} \left[ \gamma^{k} U^{t+k} \left\{ \prod_{\nu=0}^{k} \frac{\pi(A^{\nu+t}; \mathbf{S}^{\nu+t})}{\mu^{\nu+t}(A^{\nu+t}; \mathbf{S}^{\nu+t})} \right\} \left| \mathbf{S}^{t} = \mathbf{s}^{t} \right]$$

This result will form the basis of an estimating equation for  $V(\pi, \mathbf{s})$ .

### An estimating equation for $V(\pi, \mathbf{s})$ (continued)

From Lemma 3.1, it follows that

$$0 = \mathbb{E}\left[\frac{\pi(A^t; \mathbf{S}^t)}{\mu^t(A^t; \mathbf{S}^t)} \left\{ U^t + \gamma V(\pi, \mathbf{S}^{t+1}) - V(\pi, \mathbf{S}^t) \right\} \psi(\mathbf{S}^t) \right],$$

for any function  $\psi$  (an importance-weighted version of the Bellman equation). An estimating equation for  $V(\pi, \mathbf{s})$  is

$$\Lambda_n(\pi,\theta^{\pi}) = \frac{1}{n} \sum_{i=1}^n \sum_{t=1}^{T_i} \frac{\pi(A_i^t;\mathbf{S}_i^t)}{\mu^t(A_i^t;\mathbf{S}_i^t)} \left\{ U_i^t + \gamma V(\pi,\mathbf{S}_i^{t+1};\theta^{\pi}) - V(\pi,\mathbf{S}_i^t;\theta^{\pi}) \right\} \nabla_{\theta^{\pi}} V(\pi,\mathbf{S}_i^t;\theta^{\pi}),$$

where  $V(\pi, \mathbf{S}; \theta^{\pi})$  is a parametric model for the state-value function.

### **V**-learning

Given an estimate  $\hat{\theta}_n^{\pi}$ , an estimate of the value of  $\pi$  under  $\mathcal{R}$  is  $\hat{V}_{n,\mathcal{R}}(\pi) = \int V\left(\pi, \mathbf{s}; \hat{\theta}_n^{\pi}\right) d\mathcal{R}(\mathbf{s})$  and an estimate of the optimal policy is  $\hat{\pi}_n = \arg \max_{\pi \in \Pi} \hat{V}_{n,\mathcal{R}}(\pi)$ . Start with an initial policy,  $\pi$ , and repeat until convergence:

Estimate θ<sup>π</sup><sub>n</sub>
 Evaluate V
<sub>n,R</sub>(π) = ∫ V (π, s; θ<sup>π</sup><sub>n</sub>) dR(s)
 Take a step to maximize V
<sub>n,R</sub>(π) over a class of policies

# **Summary for V-Learning**

- Features of V-learning include
  - Flexibility in choosing a model for  $V(\pi, \mathbf{s}; \theta^{\pi})$
  - Online estimation, randomized decision rules
  - Flexibility in specifying reference distribution
  - Parametric value estimates
- A tailored treatment regime delivered through mobile devices may help to reduce hypo- and hyperglycemia in T1D patients

- We obtain uniform asymptotic normality for key parameters and predictions
- Main technical tools:
  - Donsker theorem for β-mixing stationary processes based on bracketing entropy (Dedecker and Louhichi, 2002)
  - New bracketing entropy preservation results for products of function classes
- Issue: Need Donsker theorems for non-stationary processes for certain types of online V-learning

### Outline

Introduction

Outcome weighted learning

Precision medicine in mHealth

### Estimation and Optimization of Composite Outcomes

Overall conclusions and future work

# Precision medicine revisited

- Patients can exhibit significant heterogeneity in response to treatment
- Outcomes can be improved by tailoring treatment to individuals
- Standard components:
  - An outcome to optimize
  - A set of treatment options
  - A set of tailoring variables
- The goal is to estimate a decision rule for treatment to optimize the outcome in a population
- How do we handle the case where there are multiple outcomes?

### Motivating example: bipolar disorder

- The Systematic Treatment Enhancement Program for Bipolar Disorder Standard Care Pathway (STEP-BD SCP)
- Characterized by episodes of depression and mania
- Anti-depressants can be used to treat depressive episodes
- Anti-depressants may induce manic episodes
- An example of precision medicine: determine which patients will benefit from anti-depressants
- Clinical decision making needs to balance the trade-off between depression and mania

### Notation

- $\mathbf{X} \in \mathcal{X} \subseteq \mathbb{R}^{p}$  are tailoring variables
- $A \in \{-1, 1\}$  is treatment
- Y and Z are two real-valued outcomes with higher values preferable

• 
$$Q_Y(\mathbf{x}, a) = \mathbb{E} \{ Y | \mathbf{X} = \mathbf{x}, A = a \}$$
 is the mean of Y given **X** and A, with  $R_Y(\mathbf{x}) = Q_Y(\mathbf{x}, 1) - Q_Y(\mathbf{x}, -1)$ 

►  $d_Y^{\text{opt}}(\mathbf{x}) = \arg \max_{a \in \{-1,1\}} Q_Y(\mathbf{x}, a) = \operatorname{sign}(R_Y(\mathbf{x}))$  is the decision to maximize Y

• 
$$Q_Z$$
,  $R_Z$  and  $d_Z^{\text{opt}}$  are defined similarly

# **Utility functions**

- ► If both Y and Z are relevant, neither d<sub>Y</sub><sup>opt</sup> nor d<sub>Z</sub><sup>opt</sup> may be acceptable
- Define the composite outcome U = u(Y, Z) for a utility function, u

▶ Define 
$$Q_U(\mathbf{x}, a) = \mathbb{E} \{ U | \mathbf{X} = \mathbf{x}, A = a \}$$
,  $R_U(\mathbf{x}) = Q_U(\mathbf{x}, 1) - Q_U(\mathbf{x}, -1)$ , and

$$d_U^{\text{opt}}(\mathbf{x}) = \arg \max_{\mathbf{a} \in \{-1,1\}} Q_U(\mathbf{x}, \mathbf{a}) = \operatorname{sign}(R_U(\mathbf{x}))$$

- ► Assume  $u(Y, Z; \omega) = \omega Y + (1 \omega)Z$ ; we will refer to  $Q_{\omega}$ ,  $R_{\omega}$ , and  $d_{\omega}^{\text{opt}}$
- ▶ For a broad class of utility functions,  $d_U^{\text{opt}}$  is equivalent to  $d_{\omega}^{\text{opt}}$  for some  $\omega \in [0, 1]$  (Butler et al., 2017)

### Pseudo-likelihood estimation of utility functions

- Assume there exists a true utility function defined by ω<sub>0</sub> such that observed decisions were made with the intent of maximizing U = u(Y, Z; ω<sub>0</sub>)
- Assume that

$$\Pr\left\{\boldsymbol{A} = \boldsymbol{d}_{\omega_0}^{\mathrm{opt}}(\boldsymbol{\mathsf{X}})\right\} = \mathrm{expit}(\boldsymbol{\mathsf{X}}^{\mathsf{T}}\beta_0)$$

for some  $\beta_0 \in \mathbb{R}^p$ 

• The likelihood for  $(\omega, \beta)$  is

$$\mathcal{L}_n(\omega,\beta) \propto \prod_{i=1}^n rac{\exp\left[\mathbf{X}_i^{\mathsf{T}}eta \mathbf{1}\left\{A_i = d_\omega^{\mathrm{opt}}(\mathbf{X}_i)
ight\}
ight]}{1 + \exp\left(\mathbf{X}_i^{\mathsf{T}}eta
ight)},$$

which can be used to estimate the true utility function and the probability that any patient would be treated optimally in standard practice

# Pseudo-likelihood estimation (continued)

- ► The likelihood for (ω, β) depends on the unknown function d<sup>opt</sup><sub>ω</sub>
- Let  $\widehat{Q}_{Y,n}$  and  $\widehat{Q}_{Z,n}$  be estimators for  $Q_Y$  and  $Q_Z$ , etc.
- For any  $\omega \in [0,1]$ , let

$$\widehat{Q}_{\omega,n}(\mathbf{x}, a) = \omega \widehat{Q}_{Y,n}(\mathbf{x}, a) + (1 - \omega) \widehat{Q}_{Z,n}(\mathbf{x}, a),$$
$$\widehat{R}_{\omega,n}(\mathbf{x}) = \omega \widehat{R}_{Y,n}(\mathbf{x}) + (1 - \omega) \widehat{R}_{Z,n}(\mathbf{x}), \text{ and}$$
$$\widehat{d}_{\omega,n}(\mathbf{x}) = \arg \max_{a \in \{-1,1\}} \widehat{Q}_{\omega,n}(\mathbf{x}, a) = \operatorname{sign}(\widehat{R}_{\omega,n}(\mathbf{x}))$$

► We can replace d<sup>opt</sup><sub>ω</sub> with d̂<sub>ω,n</sub> to obtain the pseudo-likelihood

$$\widehat{\mathcal{L}}_n(\omega,\beta) \propto \prod_{i=1}^n rac{\exp\left[\mathbf{X}_i^{\mathsf{T}} eta \mathbf{1} \left\{ A_i = \widehat{d}_{\omega,n}(\mathbf{X}_i) 
ight\} 
ight]}{1 + \exp\left(\mathbf{X}_i^{\mathsf{T}} eta
ight)}$$

### **Patient-specific utility functions**

• Let  $\theta \in \mathbb{R}^d$  and assume

$$u(Y, Z; \mathbf{X}, \theta) = m(\mathbf{X}; \theta)Y + \{1 - m(\mathbf{X}; \theta)\}Z,$$

where  $m \mapsto (0,1)$  is continuously differentiable in  $\theta$ 

• Define 
$$\widehat{d}_{\theta,n}$$
 analogously to  $\widehat{d}_{\omega,n}$ , etc.

The pseudo-likelihood is

$$\widehat{\mathcal{L}}_n( heta,eta) \propto \prod_{i=1}^n rac{\exp\left[\mathbf{X}_i^{\mathsf{T}}eta \mathbf{1}\left\{A_i = \widehat{d}_{ heta,n}(\mathbf{X}_i)
ight\}
ight]}{1 + \exp\left(\mathbf{X}_i^{\mathsf{T}}eta
ight)}$$

We need some basic assumptions and definitions, including:

expectation over X

$$\blacktriangleright \ \widehat{D}_{\theta,n}(\mathbf{x}) = m(\mathbf{x};\theta)\widehat{R}_{Y,n}(\mathbf{x}) + (1 - m(\mathbf{x};\theta))\widehat{R}_{Z,n}(\mathbf{x})$$

$$D_{\theta}(\mathbf{x}) = m(\mathbf{x};\theta)R_{Y}(\mathbf{x}) + (1 - m(\mathbf{x};\theta))R_{Z}(\mathbf{x})$$

• The density of  $D_{\theta_0}(\mathbf{X})$  at zero is  $0 < f_0 < \infty$ .

Assumptions and definitions, continued:

Assume

$$\Sigma_{0} = E \begin{pmatrix} \psi_{1Y} \\ \psi_{1Z} \\ \psi_{1A} \end{pmatrix}^{\otimes 2} = \begin{pmatrix} \Sigma_{YY} & \Sigma_{YZ} & \Sigma_{YA} \\ \Sigma_{YZ}^{T} & \Sigma_{ZZ} & \Sigma_{ZA} \\ \Sigma_{YA}^{T} & \Sigma_{ZA}^{T} & \Sigma_{AA} \end{pmatrix}$$

is positive definite (note that  $\Sigma_{AA}=\textit{I}_0)$ 

► Let 
$$a_Y(\mathbf{x}) = m(\mathbf{x}; \theta_0) R_Y(\mathbf{x}) \phi_Y(\mathbf{x}), a_Z(\mathbf{x}) = (1 - m(\mathbf{x}; \theta_0)) R_Z(\mathbf{x}) \phi_Z(\mathbf{x}), b(\mathbf{x}) = (R_Y(\mathbf{x}) - R_Z(\mathbf{x})) \dot{m}_{\theta_0}(\mathbf{x}), \text{ and } c(\mathbf{x}) = \mathbf{x} (2P_{\beta_0}(\mathbf{x}) - 1), where \dot{m}_{\theta} = \partial m / (\partial \theta)$$

▶ For any 
$$z_Y \in \mathbb{R}^{q_1}$$
,  $z_Z \in \mathbb{R}^{q_2}$ ,  $u \in \mathbb{R}^d$ , define the function  $(z_Y, z_Z, u) \mapsto k_0(z_y, z_Z, u) =$ 

$$P\left[c(\mathbf{X})\left|a_{Y}(\mathbf{X})^{T}z_{Y}+a_{Z}(\mathbf{X})^{T}z_{Z}+b(\mathbf{X})^{T}u\right|\left|D_{\theta_{0}}(\mathbf{X})=0\right]f_{0}$$

### Theorem

Under regularity conditions, the pseudo-likelihood maximizers  $\hat{\beta}_n$  and  $\hat{\theta}_n$  satisfy

$$\sqrt{n} \begin{pmatrix} \hat{\beta}_n - \beta_0 \\ \hat{\theta}_n - \theta_0 \end{pmatrix} \rightsquigarrow \begin{pmatrix} I_0^{-1} [Z_A - k_0(Z_Y, Z_Z, U)] \\ U \end{pmatrix} = \begin{pmatrix} B \\ U \end{pmatrix},$$

where  $U = \operatorname{argmin}_{u} \beta_{0}^{T} k_{0}(Z_{Y}, Z_{Z}, u)$ , and

$$\left(\begin{array}{c} Z_Y\\ Z_Z\\ Z_A \end{array}\right) \sim \textit{N}(0, \Sigma_0).$$

A certain semiparametric bootstrap is also consistent in probability.

Main technical tools:

- The Argmax theorem
- The following for the bootstrap:

### Theorem

Let H be compact with respect to a metric d and  $\mathcal{F} \subset C[H]$  be compact with respect to  $\|\cdot\|_{H}$ . For each  $f \in \mathcal{F}$ , let  $u(f) = \operatorname{argmax}_{u \in H} f(u)$ , where we arbitrarily choose a value if nonunique. Suppose also that there exists an  $\mathcal{F}_1 \subset \mathcal{F}$  such that each  $f \in \mathcal{F}_1$  has a unique maximum. Then

$$\lim_{\delta \downarrow 0} \sup_{f \in \mathcal{F}_1} \sup_{g \in \mathcal{F}: \|f-g\|_H < \delta} d(u(f), u(g)) = 0.$$

### Outline

Introduction

Outcome weighted learning

Precision medicine in mHealth

Estimation and Optimization of Composite Outcomes

Overall conclusions and future work

### **Overall Conclusions and Future Work**

- This is an exciting time for precision medicine at the confluence of machine learning and statistics.
- There are numerous open questions.
- Inference can be challenging and nonstandard.
- Consistency, or zero order inference, is often an important first step.
- This work is part of the emergence of a new (or renewed) discipline focused on data driven decision making and precision medicine and has many connections in many quantitative and nonquantitative disciplines.